These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 39093541)

  • 1. Faster steroid-free remission with tocilizumab compared to methotrexate in giant cell arteritis: a real-life experience in two reference centres.
    Quartuccio L; Treppo E; De Martino M; Pillon M; Perniola S; Bruno D; Isola M; Gremese E
    Intern Emerg Med; 2024 Aug; ():. PubMed ID: 39093541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis-study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study.
    Kreis L; Dejaco C; Schmidt WA; Németh R; Venhoff N; Schäfer VS
    Trials; 2024 Jan; 25(1):56. PubMed ID: 38225579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.
    Kötter I; Henes JC; Wagner AD; Loock J; Gross WL
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S114-29. PubMed ID: 22640655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerance of methotrexate in a real-life monocentric cohort of patients with giant cell arteritis.
    Lavergne A; Dumont A; Deshayes S; Boutemy J; Maigné G; Silva NM; Nguyen A; Gallou S; Philip R; Aouba A; de Boysson H
    Semin Arthritis Rheum; 2023 Jun; 60():152192. PubMed ID: 36963127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world Risk of Relapse of Giant Cell Arteritis Treated With Tocilizumab: A Retrospective Analysis of 43 Patients.
    Clément J; Duffau P; Constans J; Schaeverbeke T; Viallard JF; Barcat D; Vernhes JP; Sailler L; Bonnet F
    J Rheumatol; 2021 Sep; 48(9):1435-1441. PubMed ID: 33589561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations.
    Unizony S; McCulley TJ; Spiera R; Pei J; Sidiropoulos PN; Best JH; Birchwood C; Pavlov A; Stone JH
    Arthritis Res Ther; 2021 Jan; 23(1):8. PubMed ID: 33407817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients.
    Regola F; Cerudelli E; Bosio G; Andreoli L; Tincani A; Franceschini F; Toniati P
    Rheumatol Adv Pract; 2020; 4(2):rkaa017. PubMed ID: 32685912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taper versus discontinuation of tocilizumab in patients with giant cell arteritis: Real-world experience from a tertiary center.
    Nielsen MK; Nielsen AW; Donskov AO; Hansen IT; Nielsen BD; Mørk C; Hauge EM; Keller KK
    Semin Arthritis Rheum; 2024 Oct; 68():152508. PubMed ID: 38981187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab in Giant Cell Arteritis: A Real-Life Retrospective Study.
    Vitiello G; Orsi Battaglini C; Carli G; Radice A; Matucci A; Vultaggio A; Olianti C; Parronchi P; Maggi E; Cammelli D
    Angiology; 2018 Oct; 69(9):763-769. PubMed ID: 29343075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study.
    Koster MJ; Yeruva K; Crowson CS; Muratore F; Labarca C; Warrington KJ
    J Rheumatol; 2019 May; 46(5):501-508. PubMed ID: 30647171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis.
    Conticini E; Sota J; Falsetti P; Baldi C; Bardelli M; Bellisai F; Tosi GM; Frediani B; Cantarini L
    Mediators Inflamm; 2020; 2020():3203241. PubMed ID: 33061825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profile of tocilizumab and its potential in the treatment of giant cell arteritis.
    Mollan SP; Horsburgh J; Dasgupta B
    Eye Brain; 2018; 10():1-11. PubMed ID: 29416384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapse Risk and Safety of Long-Term Tocilizumab Use Among Patients With Giant Cell Arteritis: A Single-Enterprise Cohort Study.
    Samec MJ; Rakholiya J; Langenfeld H; Crowson CS; Abril A; Wang B; Mertz L; Rodriguez-Pla A; Bansal P; Burke M; Jaquith J; Weyand C; Warrington KJ; Koster MJ
    J Rheumatol; 2023 Oct; 50(10):1310-1317. PubMed ID: 37321636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis.
    de Boysson H; Le Besnerais M; Blaison F; Daumas A; Jarrot PA; Perrin F; Tieulié N; Maria A; Duffau P; Gombert B; Samson M; Espitia O; Lambert M; Mékinian A; Aouba A;
    Arthritis Res Ther; 2021 May; 23(1):143. PubMed ID: 34011407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients.
    Calderón-Goercke M; Loricera J; Moriano C; Castañeda S; Narváez J; Aldasoro V; Maiz O; Melero R; Villa JI; Vela P; Romero-Yuste S; Callejas JL; de Miguel E; Galíndez-Agirregoikoa E; Sivera F; Fernández-López JC; Galisteo C; Ferraz-Amaro I; Sanchéz-Martín J; Sánchez-Bilbao L; González-Gay MA; Hernández JL; Blanco R;
    Clin Exp Rheumatol; 2023 Apr; 41(4):829-836. PubMed ID: 36377586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension.
    Stone JH; Spotswood H; Unizony SH; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Spiera R; Bao M
    Rheumatology (Oxford); 2022 Jul; 61(7):2915-2922. PubMed ID: 34718434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.
    Strand V; Dimonaco S; Tuckwell K; Klearman M; Collinson N; Stone JH
    Arthritis Res Ther; 2019 Feb; 21(1):64. PubMed ID: 30786937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: results from the extension of the TOPAZIO study.
    Muratore F; Marvisi C; Cassone G; Ricordi C; Boiardi L; Mancuso P; Besutti G; Spaggiari L; Casali M; Croci S; Durmo R; Versari A; Di Tommaso G; Catanoso M; Giorgi Rossi P; Salvarani C
    Rheumatology (Oxford); 2024 Aug; ():. PubMed ID: 39150490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low relapse rate in patients with giant cell arteritis in a multi-centre retrospective Turkish Registry.
    Alibaz-Öner F; Kelesoglu B; Balci MA; Yardimci GK; Armağan B; Kiliç L; Karakaş Ö; Erden A; Yasar Bilge S; Kardaş RC; Küçük H; Zengin O; Tasci M; Kocaer SB; Yavuz S; Dogru A; Şahin M; Bayindir O; Sevik G; Ertürk Z; Alpay-Kanitez N; Gogebakan H; Tezcan ME; Oksuz MF; Cefle A; Kucuksahin O; Yazici A; Kasapoglu E; Bes C; Unal AU; Dalkiliç E; Yildirim Çetin G; Aksu K; Keser G; Onen F; Çobankara V; Kisacik B; Onat AM; Öztürk MA; Kaşifoğlu T; Omma A; Karadag O; Ates A; Direskeneli H
    Clin Exp Rheumatol; 2024 Apr; 42(4):816-821. PubMed ID: 37976117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis.
    Matza MA; Dagincourt N; Mohan SV; Pavlov A; Han J; Stone JH; Unizony SH
    RMD Open; 2023 Apr; 9(2):. PubMed ID: 37024237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.